Figure 3: a. A, B, C, and D: PCNA expression in skin biopsies from patient ery 004 (A and B) and ery 008 (C and D) at t0 (A and C) and tf after a 4-week treatment with Eryfotona® AK-NMSC (B and D) (amplification x10). Decreased PCNA expression at the basal layer and in upper stratum of the epidermis. b: A, B, C, and D: p21 expression in skin biopsies from patient ery 004 (A and B) and ery 008 (C and D) at t0 (A and C) and tf after a 4-week treatment with Eryfotona® AK-NMSC (B and D) (amplification x10). Decreased p21 expression at the basal layer and in upper stratum of the epidermis in both examples, the reduction being more significant in case ery 004 (A and B).